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Animals injected with  haptens  coupled to  carriers can  make hapten-specific im- 
munologic responses. In general, the strength of the anti-hapten response is propor- 
tional to the immunogenicity of the carrier; haptens on highly immunogenic carriers 
give marked anti-hapten responses, but animals made tolerant to the carrier, or ani- 
mals genetically unresponsive to the carrier, make little or no anti-hapten responses 
when  the  hapten  is presented on  that  carrier (1-5).  These  findings are usually in- 
terpreted  in  terms  of  the  current  framework of  cellular immunology as follows; B 
(bone marrow-derived) lymphocytes  L  make anti-hapten antibody only if T  (thymus- 
derived) lymphocytes can  recognize the  carrier as  "foreign" and respond to  it (6). 
(It is apparent, however, that T  cell function can be modified by graft-vs.-host reac- 
tions [7].) 
Haptens  on  nonimmunogenic  carriers are  not  inert,  however,  because  they  can 
induce hapten-specific tolerance (5, 8, 9). In this case, exposure to a  hapten on a  non- 
immunogenic carrier renders the animal incapable of making an anti-hapten response. 
Presumably, B lymphocytes recognize the hapten at first, but the T  "helper" lympho- 
cytes are not activated since they do not recognize the carrier as foreign. Furthermore~ 
the B lymphocytes must be occupied with this hapten on the nonimmunogenic carrier 
for some time, since they cannot respond to the hapten when presented later on an 
immunogenic carrier. 
These  previous  experiments  have  mainly  analyzed  serum  antibody  re- 
sponses  to  the  hapten.  Here,  we present  a  system in which  a  hapten  (NIP) 
coupled to an isologous carrier (mouse "y-globulin) can provoke a hapten-specific 
immune response if given in adjuvant,  and can elicit hapten-specific tolerance 
if given in  saline. 
Materials and Methods 
Animals.--Adult  inbred mice of the strains (ACA X  CBAF1), BALD~e, and LAF1  were 
used. 
* Supported in part by grants AM10145 and  AI-TI00013  from  the U.S.  Public Health 
Service. 
1Abbreviations used in  this paper: B  lymphocytes, bone  marrow-derived  lymphocytes; 
BSA,  bovine  serum  albumin;  CFA,  complete Freund's adjuvant;  EACA,  epsilon-amino- 
cap  roic acid; M~/G, mouse gamma globulin; NIP, 4-hydroxy-3-1odo-5-nitrophenylacetic  acid; 
OA,  ovalbumin;  PFC,  plaque-forming  cells;  PHA,  phytohemagglufinin;  SRBC,  sheep 
erythrocytes; T-3H, tritiated thymidine; T lymphocytes, thymus-derived lymphocytes. 
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Antigen.--Mouse  immunoglobulin (M'yG) was  prepared from sera or ascites of BALB/c 
mice carrying a  mineral oil-induced  tumor MOPC-21  with 5,1  specificity  (a  gift from  Dr. 
Howard  Grey).  The M'J'G was  purified by ammonium sulfate precipitation and Sephadex 
G-200 filtration (Pharmacia Fine Chemicals, Inc., Piscataway, N.  J). The hapten used was 
4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP). Hapten-protein coupling was accomplished 
by the method of Brownstone et al.  (10)  and yielded a  ratio of 8-10 NIP  per molecule of 
NIP-M~G, bovine serum albumin (BSA) (Pentex Biochemical, Kankakee, Ill.), or ovalbumin 
(OA)  (Miles Lab.,  Inc., Elkart, Ind.). 
Immunization.--BALB/c  mice were  immunized  intraperitoneally with 400  #g  of  NIP- 
M'yG in complete Freund's adjuvant (CFA)  (Difco Laboratories, Inc., Detroit, Mich.). 
Tolerization.--Tolerization  was  accomplished by treating (ACA  X  CBA)  or LAF1  mice 
with 1 mg of soluble NIP-M'),G three times weekly for 3-4 wk, intraperitoneally. Untreated 
mice served as controls. After a  rest period of  10 days the tolerized and normal mice were 
challenged with either 0.2 mg of NIP-OA (CFA) in the footpads of the hind legs or with 0.4 
mg of NIP-MTG (CFA), intraperitoneally. 
In  Vitro Stimulation  of DNA  Synthesis.--For  in  vitro  study,  the  stimulation of  DNA 
synthesis by antigen was studied in a  manner similar to that of Dutton and Eady  (11).  4 
million spleen cells from immunized or tolerant mice were cultured with different concentra- 
tions of antigen in 1 ml of RPMI-1640 media  (Grand Island Biological Co., Grand Island, 
N.  Y.)  containing 5% heat-inactivated rat serum,  100 units of penicillin G, and  100 #g  of 
streptomycin/ml. 3  days after culturing the cells in triplicate at 37°C  in a  humidified  CO2 
incubator  (5%  CO~. and 95% air),  1 #Ci  of tritiated thymidine  (T-~H)  (Schwartz/Mann, 
Div. Becton, Dickinson, & Co., Orangeburg, N. Y.)  (6 Ci/mmole) was added for 5 hr. DNA 
synthesis was  determined  by  precipitating  trichloroacetic acid-insoluble material  on  glass 
fiber filters (Whatman GF/C grade) and by counting in a Packard Tri-Carb liquid scintillation 
spectrometer (Packard Instrument Co., Downers Grove, Ill.) 
In Vitro Blocking of DNA Syntl~sis.--4 million spleen cells from mice immunized, as before 
mentioned, were incubated for 3  hr at 37°C  with different concentrations of NIP-epsilon- 
amino-caproic acid  (NIP-EACA)  prepared according to  Brownstone et al.  (10)  before  the 
stimulatory  antigen  was  added.  The  NIP-EACA  was  not removed and after addition of 
antigen, the experiments were performed in the regular manner. 
Serological Tests.--Sera  of mice were tested for anti-NIP antibody by an indirect hemolytic 
assay  (12).  Threefold dilutions of sera were made and equal volumes of  NIP-coated sheep 
erythrocytes (SRBC) and complement were added.  The tubes were then incubated at 37°C 
for 30 min. The reciprocal of the dilution that gave complete lysis was considered the titer of 
that serum. Uncoated SRBC were used as control. The antigen-binding capacity  of sera from 
control and tolerant mice was determined by a modified Farr assay (10).  For (ACA  X  CBA) 
mice anti-NIP response was measured as micrograms of antigen bound per 1  ml of undiluted 
serum at 50% binding using 10  -6 ~  BSA-125I.  The results for LAF1  mice are per cent anti- 
gen precipitated at 1:3 serum dilution using 10  -9 M EACA-NI25IP. 
Antibody Synthesis In Vitro.--The number of cells in the spleen forming antibodies against 
NIP was determined by a modification of the localized hemolysis-in-gel technique (13)  using 
NIP-coated  SRBC and uncoated SRBC as controls. The plaque-forming cells (PFC)  deter- 
mined was a  total of direct and indirect plaques. Rabbit anti-mouse "),1 and "y2a antisera (a 
gift from Dr. Roy Woods, Immunoglobulin Reference Center, Me]oy Inc., Falls Church, Va.) 
were used to develop indirect plaques. 
RESULTS 
Immunogenicity  of  NIP-M'yG.--The  immunogenicity  of  NIP-M~/G  was 
determined  by  immunizing  mice  with  this  antigen  in  CFA  according  to  the 
protocol  indicated  in Materials  and  Methods.  2-4 wk  after immunization  the 
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TABLE  I 
Stimulation of Primed Mouse Spleen Cells by Hapten-Isologous Carrier 
Antigen in vitro  ~g/Culture  Exp.  1  Exp. 2  Exp. 3 
cpm/culture  ~  SE 
0  ---  1421  4-  399  1001  4-  221 
NIP-M~/G  100  5575  4-  1346  14,170  ±  392 
NIP-!ViTG  500  22,558  4-  899  18,968  +  1269 
MTG  100  1759  4-  126  961  4-  216 
M3'G  500  1584  4-  42  1140  4-  225 
NIP-EACA  10 
NIP-EACA  150 
613  i  94 
15,822  4-  2365 
672  -¢-  34 
470  +  95 
BALB/c female mice were immunized i.p. with NIP-M'yG (CFA). 2-4 wk later, 4 X  106 
spleen cells were cultured with antigens for 3 days and pulsed with 1/~Ci T-3H for 5 hr. Re- 
sults are expressed as counts per minute per culture. (Mean of triplicates -4- standard error.) 
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FIG.  1.  3  Uptake of thymidine- H in vitro by cells from mice primed with NIP-M3,G (CFA). 
4  X  106 spleen cells from primed mice were cultured for 3 days with varying concentrations 
of NIP-MTG or M76. Thymidine-3H was added for last 5 hr of culture. Results are expressed 
as counts per minute (CPM) per culture tube and graphed as mean 4- sE of triplicates. CURLA  S.  WALTERS,  JOHN  W.  MOORttEAD~  HENRY  N.  CLAMAN  549 
titers of these mice were also determined. Spleen cells from these mice produced 
an average of 500 NIP-specific hemolytic plaques per spleen.  (Nonimmunized 
mice had no NIP-PFC by this technique.) The sera had a mean hemolytic titer 
of 1:243  4-  102 using complement-dependent ]ysis of NIP-SRBC.  Control sera 
were negative by this method.  In vitro cellular studies shown in Table I  and 
Fig.  1  indicate that  NIP-M~/G was  effective in  triggering secondary antigen- 
dependent  DNA  synthesis in  spleen  cells, while  M~G  alone had  little or  no 
stimulatory effect. NIP-EACA did not stimulate by itself, indicating that  the 
triggering mechanism  involved more  than  interaction with  one NIP  determi- 
nant  coupled  to  a  single  amino  acid.  Therefore,  the  hapten  coupled  to  the 
carrier  was  stimulatory  although  neither  the  hapten  nor  the  carrier  alone 
initiated DNA synthesis. 
TABLE II 
llapten Inhibition by NIP-EA CA of In Vitro Stimulation by NIP-M'yG 
NIP-M~G  NIP-EACA 
Exp. 1  Exp. 2 
cpm/Culture  Per cent  cpm/Culture  Per cent 
inhibition  inhibition 
#g/Culture  i*g/Culture  %  % 
0  0  613  -4- 94  --  304  4-  33  -- 
500  0  15,822  4-  2365  --  4148  4-  475  -- 
500  1  13,640  -4-  784  14.3  4561  4-  149  0 
500  10  12,537  4-  799  21.6  3159  4-  288  25.7 
500  50  9670  4-  760  40.5  2648  4-  244  39.0 
500  100  8360  4-  1402  50.9  2379  4- 300  46.0 
500  150  9622  -t- 910  40.6 
Spleen cells from mice primed with NIP-M'yG (CFA) as in Table I  were cultured for 3 
hr with NIP-EACA before NIP-M'yG was added for the remainder of the 3 days. Cultures 
and results are expressed as in Table I. 
The Specificity  of the In  Vitro  Response for  the  NIP  Determinant.--To  de- 
termine how much  of the in vitro response could be attributed to the hapten, 
NIP-EACA was used as a  blocking agent, this being more efficient in blocking 
a  hapten-specific  reaction  than  the  hapten  alone  (10).  The  results  of  such 
experiments  (Table  II)  indicate  that  almost  50%  of  the  response  could  be 
blocked with  a  concentration  of  100  #g  of NIP-EACA.  This  inhibition  was 
hapten-specific because  at  a  similar concentration  the  hapten  had  no  inhibi- 
tory  effect  on  phytohemagglutination  (PHA)  stimulation or  on  the  in  vitro 
response  of  cells  primed  to  and  stimulated  by  an  irrelevant  antigen  (oval- 
bumin). 
Tolerance  to  NIP-M'),G.--To  further  substantiate  the  hapten-specific  re- 
sponse,  mice were made  tolerant to  the hapten  by pretreatment with  soluble 
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NIP-OA (CFA). The results in Table III indicate that  the  mice pretreated 
with soluble NIP-M'yG had a  markedly reduced antibody response. The tol- 
erance  weakened  as  the  interval  of  time  lengthened  after  challenge  with 
NIP-heterologous carrier. The hapten-specific tolerance in these  experiments 
is emphasized by the fact that these mice had a normal response to the hetero- 
logous carrier (i.e. BSA) to which the challenge NIP was coupled. 
TABLE III 
Effect of Pretreatment with NIP-M'yG on the Immune Response to NIP 
Mouse strain 
(No. of mice) 
ACA  X  CBA 
Control (6) 
Tolerant (8) 
Control (6) 
Tolerant (8) 
Control (6) 
Tolerant (8) 
LAFx 
Control 
Tolerant 
Control 
Tolerant 
Pretreatment 
None 
NIP-M3'G 
None 
NIP-M3,G 
None 
NIP-M'yG 
None 
NIP-M~/G 
None 
NIP-M3~G 
Challenge 
antigen (CFA) 
NIP-BSA 
NIP-BSA 
NIP-BSA 
NIP-BSA 
NIP-BSA 
NIP-BSA 
NIP-OA 
NIP-OA 
NIP-OA 
NIP-OA 
Time 
after 
chal- 
lenge 
days 
15 
15 
22 
22 
32 
32 
15 
15 
21 
21 
Mean anti-NIP 
-I- sE 
1.56  4- 0.397 
0.03  4- 0.034 
11.10  4-  2.34 
0.07  4-  0.023 
16.08  4-  2.079 
0.71  4- 0.175 
36.  4-  5.48 
2.1  4-  0.8 
76.  4-  4.5 
25.3  -4- 2.73 
Mean anti-BSA 
-4- SE 
19.03  4- 3.78 
20.16  4-  3.26 
0.95  4- 0.14 
0.95  4-  0.08 
1.72  4-  0.17 
1.79  4-  0.16 
Pretreated  mice were injected 3 X weekly for 4 wk with soluble NIP-M2zG. Control mice 
were not injected. After  10 days rest,  all mice were challenged with 0.2 mg of NIP-BSA 
(CFA) or 0.2 mg of NIP-OA (CFA) in the footpads and the antigen-binding capacity of the 
serum  was  detected  at intervals thereafter.  For ACA >(  CBA mice, anti-NIP response 
measured as/zg bound/ml serum at 50% binding, using 10  -6 ~t EACA-N125IP and anti- 
BSA response measured as #g bound/ml serum at 50% binding using 10  -6 M  BSA-125I. For 
LAF1 mice, results  are per  cent antigen precipitated  at 1:3  serum dilution using  10  --g 
EACA-N125Ip. 
Further experiments were done testing hapten-specific tolerance induced by 
soluble NIP-M'I,G by  chMlenging in vivo with  the  same  antigen in a  form 
known to be immunogenic, namely NIP-M~/G in CFA, and then stimulating 
the  cells in vitro using NIP-M3'G. Untreated LAF1 mice  challenged in vivo 
with NIP-M3'G (CFA)  had  spleen cells capable of responding to NIP-MTG 
in vitro with a dose-dependent increase in T-3H uptake as in Table I  and Fig. 1, 
but mice pretreated with soluble NIP-M3'G did not show this stimulation of 
thymidine uptake  (Table  IV).  In  neither  case  did  carrier  alone  stimulate 
T-3H uptake. This lack of stimulation further substantiates an in vitro hapten- 
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TABLE IV 
Effect of Pretreatment of Mice with Soluble NIP-MTG on In Vitro Challenge of Cells Immunized 
with NIP-MS'G (CFA) 
Antigen in vitro  gg/Culture  Control  Tolerant  Time after 
challenge 
NIP-MTG 
NIP-M3'G 
NIP-M3'G 
NIP-MTG 
Mh'G 
Mh'G 
PHA 
m 
NIP-M3'G 
M3'G 
PHA 
cpm/Culture  4- BE  Days 
0  1790 4- 447  1014 4- 455  17 
10  4244 4- 317  1280 4- 266 
50  7175 4-  575  1208 4- 348 
100  8617 4-  666  1810 -+- 796 
500  15,517  4- 927  1912 -4- 898 
100  2033 4-  10  819  ±  98 
500  2421 4- 398  1001 4-  68 
17,399  4-  1134  22,665  4-  1021 
0  737  4-  111  995  4- 96  23 
500  6334 4-  225  3516 4- 630 
500  1003 4-  194  1206 -4- 211 
4159 4- 454  9247 4- 429 
LAF1 mice were untreated (control) or treated  3 X weekly for 4 wk with 1 mg of soluble 
NIP-M3'G (tolerant).  After a  10 day rest,  all mice were given i.p.  0.4 mg of NIP-M3'G 
(CFA). Spleen cells were cultured  17 and 23 days later as in Tables I and II and results ex- 
pressed as cpm 4- s~/culture. 
DISCUSSION 
The  results  reported  in  this  paper  demonstrate  that  both  hapten-specific 
immunity and tolerance can be induced in mice using the hapten NIP coupled 
to  isologous  mouse  gamma  globulin.  Injection  of  the  antigen  (NIP-M3'G) 
mixed with CFA elicits hapten-specific immunity as measured by NIP-specific 
PFC,  specific  binding  of N125IP  by immune  serum,  and  by  antigen-driven 
DNA  synthesis  in  vitro.  Hapten-specific  tolerance  was  induced  by injecting 
the antigen in soluble form. Mice treated in this way and challenged with the 
hapten  coupled  to  M'yG  or  a  heterologous  carrier  had  a  markedly  reduced 
antibody response to NIP, and their spleen cells did not respond with increased 
DNA synthesis in vitro when mixed with NIP-M3,G. 
Hapten-specific immunity and stimulation  of primed  cells in vitro has been 
reported previously using guinea pigs immunized with DNP coupled to guinea 
pig  albumin  or DNP  coupled  to heterologous  carriers  (1,  7,  11,  14).  Specific 
tolerance induced by treatment with DNP coupled to nonimmunogenic carriers 
such  as  mouse  serum  or polypepfides  has  also  been  shown  (5,  9).  However, 
hapten-specific  cell  stimulation  in  vitro  invoked by NIP-M3'G which  can be 
abolished by inducing NIP-specific tolerance has not been previously demon- 
strated. We have shown that spleen cells from mice primed with NIP-Mq'G in 
CFA  can  be  triggered  by  the  antigen  to  give  a  secondary  type  response  in 552  IMMUNITY  AND  TOLERANCE  TO  HAPTEN-ISOLOGOUS  CARRIERS 
vitro, as measured bv increased DNA synthesis. The concentrations of antigen 
used in  this  system for immunization and  stimulation  are much higher than 
those used in a different hapten-isologous carrier, i.e., DNP-guinea pig albumin 
(15).  This indicates  that  our NIP-M3'G  is  not highly immunogenic in  vivo. 
Recent experiments have shown that 200 ttg of NIP-Mq'G can be immunogenic 
in vivo. 500 #g of NIP-MTG in vitro, although not optimal, gave much better 
increment over background than lower concentrations (Fig.  1). Therefore, we 
chose this as our stimulatory dose in vitro in most experiments. The in vitro 
response requires both the hapten and carrier since neither by itself is capable 
of stimulating the cells. This is similar to the findings of others (7, 11). Although 
the carrier by itself did not stimulate  the cells,  the response had a great deal 
of carrier specificity. This was shown in the experiment in which cells primed 
to  NIP-MyG  gave  a  fivefold  response  when  the  stimulatory  antigen  was 
NIP-M~G (500/xg) and only a twofold response when the stimulatory antigen 
was NIP-OA (500/~g). This finding confirms the fact that the "carrier effect" 
is not absolute and that hapten coupled to a heterologous carrier can be weakly 
stimulatory (11). 
The participation of the hapten in  the in vitro response was demonstrated 
by  blocking  experiments.  Nearly  50%  of  the  in  vitro  DNA  response  was 
blocked by the addition of NIP-EACA. This strongly suggests that a significant 
portion of the response is  due  to  the hapten.  This blocking corroborates the 
findings of others (1, 14),  although in our hands  significant blocking occurred 
when free hapten was in 10-fold excess compared with hapten carrier. At higher 
concentrations  NIP-EACA  was  somewhat  toxic for  the  cells  which  masked 
any further blocking  that  might be obtained.  Preliminary experiments indi- 
cate that M'yG (which had no stimulatory effect) also had no blocking effect. 
Final interpretation of these results rests  on  the  identification of  the  cells 
involved in responsiveness or unresponsiveness to both NIP and M~G. Although 
this  is  not possible  at present,  it is  clear  that NIP-MTG  (CFA)  stimulates 
the  production of hapten-specific antibody  (presumably by B  lymphocytes) 
(15)  as shown by serum NIP-hemolysins and NIP-PFC in the spleen. Accord- 
ing to the  current concepts outlined above, hapten-specific antibody produc- 
tion by B  lymphocytes requires T  cell help (6). In  the context of our experi- 
ments,  immunogenicitiy is  acquired via  the  coupling of NIP  to  M'yG.  This 
implies  that helper ceU activity in vivo arises from T  cell recognition of the 
NIP-MTG  complex (16).  A  similar  situation  applies  to the in vitro stinmla- 
tion of cells primed to NIP-MTG (CFA) in that antigen-driven DNA synthesis 
occurs with  the  complex, NIP-Mh'G,  but not with  Mq'G  alone,  either in its 
native form or as M3'G "sham-coupled to NIP" (i.e.,  put through the coupling 
procedure  in  the  absence  of NIP,  unpublished  observations).  Although  the 
bulk  of  antigen-stimulated  DNA  synthesis  in  vitro  is  probably  due  to  re- 
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with  anti-theta  serum and  complement,  2 the participation  of NIP-specific B 
cells is as yet undetermined. 
In  tolerant  systems  involving  proteins,  it  is  clear  that  unresponsiveness 
may inhere in T  cells,  B  cells,  or both (17). In our hapten-conjugate system, 
antibodies capable of binding NIP were scarcely detectable when the tolerant 
mice were challenged with NIP  on either the  tolerizing carrier,  M3,G,  or on 
an unrelated carrier, BSA. (Both tolerant and control mice made good responses 
to BSA.)  Tolerance is  therefore directed specifically to  the  hapten,  and  the 
current hypothesis would interpret this to mean hapten-specific blockade of B 
lymphocytes (18). 
The failure of NIP-M3,G to stimulate cells from tolerant mice in vitro (Table 
IV)  has  additional  implications,  we  believe.  Since mice immunized  to NIP- 
M3,G  have  cells  capable of recognizing NIP-M3'G  (but  not  M~,G  alone),  it 
appears that in tolerant mice these cells  are either lacking or are inactivated. 
Since many of  these cells are probably T  cells,  this implies that mice tolerant 
to NIP-M3,G have B  cell  tolerance (to NIP)  as  well as T  cell tolerance (to 
NIP-M3,G). 
The ability to produce either hapten-specific immune responses or tolerance 
using "isologous carrier" with or without adjuvant, and the ability to measure 
these responses at the cellular level, have significant implications for the study 
of autotolerance and autoimmunity. 
SUMMARY 
A hapten, 4-hydroxy-3-iodo-5-nitrophenylacetic  acid (NIP) when coupled to 
isologous  mouse  gamma  globulin  (M'yG)  elicits  a  hapten-specific  immune 
response in mice if administered in Freund's complete adjuvant. This response 
is measurable by the capacity of the sera  to bind N125IP, by detection of NIP- 
specific plaque-forming cells (B cells), and by in vitro secondary type antigen- 
driven  DNA synthesis  (T cells and probably B  cells). The in  vitro response 
requires both the hapten and carrier since neither by itself is capable of stimu- 
lating the spleen cells. This same antigen gives rise to hapten-specific tolerance 
when given in the soluble form. Mice pretreated with soluble NIP-M~/G and 
challenged with NIP coupled to a heterologous carrier give a normal antibody 
response to the carrier but have barely detectable levels of antibody to NIP. 
Spleen cells from mice made tolerant to N[P-M~,G do not respond in vitro with 
increased  DNA  synthesis.  This implies  that  thymus-derived  cells as  well  as 
bone marrow-derived cells are involved in hapten-specific tolerance. 
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